Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity - Additional Information (Details)

v3.21.1
Stockholders' Equity - Additional Information (Details) - USD ($)
 3 Months Ended
Jan. 01, 2021
Mar. 31, 2021
Dec. 31, 2020
Jun. 30, 2020
Jun. 04, 2020
Nov. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Common Stock, Shares Authorized   95,000,000 95,000,000   95,000,000  
Common Stock, Increase in authorized shares (in shares)         35,000,000  
Common Stock, Par or Stated Value Per Share   $ 0.0001 $ 0.0001   $ 0.0001  
Common Stock, Shares, Issued   72,163,822 62,420,439      
Common Stock, Shares, Outstanding   72,163,822 62,420,439      
Shelf Registration Statement, Maximum Authorized Securities           $ 100,000,000
Issuance of common shares, net of offering costs - At-the-market offering   $ 23,893,000        
Issuance of common shares - Founders Agreement   634,000        
Shelf registration statement remaining authorized securities   71,300,000        
Non-vested Restricted Stock [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Total unrecognized compensation cost related to non-vested   $ 4,200,000        
Weighted average period (in years)   2 years        
Performance Shares [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Restricted stock outstanding non-vested   333,334        
2015 Incentive Plan [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Number of shares available for issuance Authorized       9,000,000    
Plans expires (in years)   10 years        
Shares are available for issuance   3,458,465        
At the Market Offering [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Number of shares sold   7,025,309        
Sale price per share   $ 3.50        
Gross proceeds from issue of shares   $ 24,600,000        
Net proceeds from the offering   $ 23,900,000        
Stock Issued During Period Shares Common Shares For At The Market Offering   7,025,309        
Stock Issued During Period Value Common Shares For At The Market Offering Gross   $ 24,600,000        
Issuance of common shares, net of offering costs - At-the-market offering   23,900,000        
Commissions and other transaction costs   $ 700,000        
Fortress Biotech, Inc [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Number of shares sold 1,742,449 175,625        
Percentage of annual equity fee 2.50% 2.50%        
Issuance of common shares - Founders Agreement   $ 634,000        
Agent [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Commission rate   3.00%        
Common Class A [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Common Stock, Shares Authorized         7,000,000  
Common Stock, Shares, Issued   7,000,000 7,000,000      
Common Stock, Shares, Outstanding   7,000,000 7,000,000